Keywordsvaccine; adjuvants; Sporothrix schenckii; toluene; virulence; enolase; Montanide PetGel A; Amphotericin B; cutaneous leishmaniasis; hydrogel; wound dressing; controlled release; thermoreversible gel; poloxamer 407; candidiasis; amphotericin B; skin and vaginal mucosa; butenafine; SNEDDS; solid SNEDDS; spray drying; leishmaniasis; design of experiments; orodispersible films; fast-dissolving films; micelles; amphotericin B; fungal infections; aspergillosis; amphotericin B; oral delivery; chitosan; shiitake; Lentinula edodes; AHCC®; Molecular Envelope Technology; praziquantel; calcium carbonate; schistosomiasis; bioavailability; solubility; cytotoxicity; fluconazole; orthopedic infection; Poly(d,l-lactide-co-glycolide) beads; sustained release; Leishmania infantum; cutaneous leishmaniasis; meglumine antimoniate; Sepigel 305®; topical treatment; Amphotericin B; polymer micelles; drug delivery; liposomes; transferosomes; nanoparticles; emulsions; candidiasis; aspergillosis; azoles; amphotericin B; combined therapy; quality by design; leishmaniasis; malaria; trypanosomiasis
